Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
✉ Email this page to a colleague
Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-02-23 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | Jennifer L. Hall |
| Patents | 10,029,015; 10,046,031; 10,046,058; 7,579,473; 8,039,009; 8,039,030; 8,044,014; 8,048,017; 8,877,776; 9,000,021; 9,005,016; 9,018,017; 9,024,034; 9,040,034; 9,056,059 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-11-20 | 162 | - Transcript | 1 A. These are two Mylan patent documents that report 10:46:31 2 Mylan form M-1 through M-… '015 patent 11:18:29 19 patentably distinct over Claim 5 of the '473 patent? 11:18:32 … So the Patent Office allowed -- the Patent Office had 11:26:09 7 the '473 patent during prosecution…;349 patent was known in the art before the 08:39:56 19 priority date of the '349 patent; correct… blocking patent? 09:31:20 23 A. Well, my understanding is if there's a patent 09:31:23 | External link to document |
| 2023-11-20 | 163 | - Transcript | in that category; 03:10:28 14 correct? 03:10:29 15 A. Yes. 03:10:31 16 Q. Okay. …#x27;349 patent and the objective indicia. 09:20:39 24 A. Well, the '349 patent was crucial…x27;349 patent; correct? 10:47:04 19 A. Correct. 10:47:05 20 Q. What patents will you…:41:09 3 patents in the same order. 11:41:11 4 Q. And what do these patents generally disclose…different patents, not the asserted crystalline malate 11:53:46 13 cabozantinib patents. This | External link to document |
| 2023-12-12 | 167 | Post Trial Brief | ’s ANDA Products infringe Exelixis’ U.S. Patent No. 7,579,473, which covers cabozantinib. D.I. 331 (Final…439 patent U.S. Patent No. 11,091,439 (JTX-001) ’440 patent U.S. Patent No. …015 patent U.S. Patent No. 11,098,015 (JTX-003) ’349 patent U.S. Patent No. … claim 3 of U.S. Patent No. 11,298,349 (“the ’349 patent”). The ’349 patent is directed to a …including claim 4 of U.S. Patent No. 11,091,439 (“the ’439 patent”), claim 3 of U.S. Patent No. 11,091,440 (“ | External link to document |
| 2024-01-23 | 175 | Post Trial Brief | ’473 patent U.S. Patent No. 7,579,473 (DTX-13) ’776 patent U.S. Patent No. 8,877,776…’439 patent U.S. Patent No. 11,091,439 (JTX-1) ’440 patent U.S. Patent No. 11,091,440…’015 patent U.S. Patent No. 11,098,015 (JTX-3) ’349 patent U.S. Patent No. 11,298,349… ’439 patent, ’440 patent, ’015 patent, and ’349 Patents-in-Suit …the ’440 patent and ’015 patent would have been patentably indistinct over the ’473 patent. | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
